ReGenTree and Ora will mutually start testing the ReGenTree’s new drug RGN-259 for the treatment of dry eye syndrome, in a clinical study named ARISE-3, based entirely on the results of a previous clinical trials, ARISE-1 and ARISE-2.
According to certain officials at ReGenTree, cited in the press release, the study will enroll 700 patients into the trial.
The treatment should be completed in the first half of 2020, it has been said in the same announcement.
ReGenTree is a U.S. joint venture company owned by GtreeBNT Co., Ltd, and RegeneRx Biopharmaceuticals, Inc. specifically to develop RGN-259 in both the USA and Canada for ophthalmic indications. ReGenTree licensed the rights to RGN-259 from RegeneRx in 2015.